Anti-tumor medicinal and edible composition and application thereof

Abstract

The invention discloses an anti-tumor medicinal and edible composition and application thereof, and belongs to the technical field of traditional Chinese medicine preparations. The invention discloses an anti-tumor medicinal and edible composition and application thereof. The composition is prepared by mixing a main medicine and an auxiliary medicine. Wherein the main medicines comprise dandelion, lucid ganoderma, cordyceps militaris, chrysanthemum, honeysuckle, orange peel, dendrobium officinale and myristica fragrans; meanwhile, lentinula edodes, chestnut mushroom, American ginseng, liquorice, kudzuvine root, turmeric, dogwood and fruits rich in procyanidine are used as auxiliary materials, wherein cranberries, mulberries and lemons have the effects of adjusting the taste and assisting in resisting tumors. The medicinal and edible composition disclosed by the invention is high in safety, scientific in formula and stable in process, can remarkably resist tumors, and has remarkable social and economic benefits. Fruits rich in procyanidine are added, so that the effects of adjusting the mouth feel and assisting in resisting tumors are achieved.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine preparations, and in particular to an anti-tumor medicine-food composition and application thereof. Background Art

[0002] Tumors are diseases in which cells in the body, due to gene mutations, repair disorders, and uncontrolled proliferation, undergo malignant growth and spread to other sites. The pathogenesis of tumors is complex, involving multiple factors, including genetic, immune, and environmental factors. Key characteristics of tumor cells include proliferation, metastasis, resistance to apoptosis, and immune evasion. Modern medicine believes that tumor development is often caused by gene mutations, particularly those related to cell cycle regulation, DNA repair, apoptosis, and cellular metabolism. The accumulation of mutations leads to cellular dysfunction, ultimately transforming into cancer cells. Tumors are not merely composed of cancer cells but also encompass the tumor microenvironment. Immune cells, blood vessels, fibroblasts, and other components of the tumor microenvironment contribute to tumor growth and metastasis. Tumor cells can evade host immune surveillance by producing immunosuppressive molecules (such as PD-L1) that suppress T cell function, thereby avoiding recognition and elimination by the immune system. The remarkable heterogeneity of tumor cells within a single tumor makes cancer treatment challenging. Genetic and phenotypic differences between tumor cells can make some cells resistant to treatment, leading to treatment failure and tumor recurrence.

[0003] Currently, conventional anti-cancer treatments commonly used on the market include surgical resection, radiotherapy, chemotherapy, and targeted therapy. However, these methods are often associated with significant side effects and have limited therapeutic efficacy, especially in patients with advanced cancers, where recurrence rates are high. While chemotherapy drugs can kill tumor cells, they can also have adverse effects on normal cells, such as bone marrow suppression, digestive system reactions, and hair loss. Radiotherapy also faces the inevitable risk of radiation damage, and long-term use may cause local tissue damage.

[0004] In recent years, targeted therapy and immunotherapy have become innovative approaches in cancer treatment. Targeted drugs kill tumor cells by targeting specific molecular pathways, demonstrating good selectivity and low side effects. Immune checkpoint inhibitors, such as PD-1 / PD-L1 inhibitors and CTLA-4 inhibitors, activate the patient's own immune system to attack tumor cells, an approach that has demonstrated significant efficacy in some tumor types. However, challenges remain, including high costs, inconsistent therapeutic effects, and poor adaptability to certain tumor types.

[0005] In recent years, with the advent of the concept of "medicine and food have the same origin," research on Traditional Chinese Medicine (TCM) in the field of anti-tumor medicine has increased rapidly. TCM, characterized by its complex composition, broad scope, and multi-targeted therapeutics, can exert its anti-tumor effects through multiple mechanisms. Compared with traditional chemotherapy and targeted drugs, TCM's anti-tumor advantages lie in its typically multi-component, multi-targeted active ingredients, which can simultaneously act on multiple aspects of tumor cell proliferation, metastasis, and apoptosis, modulating the tumor microenvironment and thereby achieving a comprehensive tumor inhibitory effect. Compared with chemotherapy drugs, TCM generally exhibits lower toxicity and side effects in clinical use. TCM ingredients with the same origin as food and medicine are safer and suitable for long-term use. They can not only inhibit tumor growth but also improve patients' immune function and mitigate the side effects of chemotherapy and radiotherapy. TCM has unique advantages in enhancing immunity. TCM cancer treatment focuses not only on tumor suppression but also on improving patients' overall health. For example, certain TCM ingredients can relieve pain, increase appetite, and reduce fatigue, thereby improving patients' quality of life.

[0006] With the advancement of traditional Chinese medicine (TCM) extraction technology and modern medical technology, TCM anti-tumor treatment will enter a new stage of development. Standardized research on the anti-tumor efficacy of TCM will provide more evidence for clinical application. Through clinical validation and large-scale multicenter studies, the safety and efficacy of TCM in anti-tumor treatment will be further demonstrated. Modern drug design and screening technologies will enable the discovery of more TCM ingredients with anti-tumor activity and the development of new anti-tumor drugs. These drugs may have greater specificity and fewer side effects. In the future, the combination of TCM with modern treatments such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy will become an important strategy for improving anti-tumor efficacy. By combining different treatment approaches, the limitations of single therapies can be overcome and therapeutic efficacy can be enhanced. Summary of the Invention

[0007] The purpose of the present invention is to provide an anti-tumor medicine-food composition and its application to solve the problems existing in the above-mentioned prior art.

[0008] To achieve the above object, the present invention provides the following solutions:

[0009] One of the technical solutions of the present invention is a medicine-food composition with anti-tumor effect, comprising the following ingredients in parts by weight: 10-30 parts of dandelion, 5-15 parts of ganoderma lucidum, 20-40 parts of cordyceps militaris, 10-30 parts of chrysanthemum, 20-40 parts of honeysuckle, 10-30 parts of tangerine peel, 20-40 parts of dendrobium officinale and 20-40 parts of nutmeg.

[0010] The second technical solution of the present invention is a method for preparing the edible and medicinal composition, comprising the following steps:

[0011] (1) mixing and crushing dandelion, Ganoderma lucidum, Cordyceps militaris, chrysanthemum, honeysuckle, orange peel, Dendrobium officinale and nutmeg, and extracting with ethanol to obtain extract I;

[0012] (2) Mixing and grinding shiitake mushrooms, chestnut mushrooms, American ginseng, liquorice, kudzu root, turmeric, and cornus officinalis to obtain a powder; blending cranberries, mulberries, and lemons to obtain a coarse pulp; mixing the powder and the coarse pulp, and extracting with ethanol to obtain extract II;

[0013] (3) Combine the extracts I and II, evaporate and concentrate, and add auxiliary materials to prepare granules.

[0014] The third technical solution of the present invention is the use of the medicine-food composition in the preparation of anti-tumor drugs.

[0015] Based on the above technical solution, the present invention has the following technical effects:

[0016] (1) The present invention screens the anti-tumor activity of multiple medicinal and edible plants, and then optimizes the formula based on traditional Chinese medicine theory and modern medical technology. It determines that the medicinal and edible plants are composed of dandelion, ganoderma lucidum, cordyceps militaris, chrysanthemum, honeysuckle, tangerine peel, dendrobium officinale, and nutmeg as the main ingredients, and one or more of shiitake mushrooms, chestnut mushrooms, American ginseng, liquorice, kudzu root, turmeric, cornus officinalis, cranberry, mulberry, and lemon as auxiliary ingredients to achieve the auxiliary anti-tumor effect.

[0017] (2) The anti-tumor composition of the present invention uses Chinese medicinal and edible herbs as main raw materials, is highly safe, has no toxic side effects, can be taken for a long time, effectively avoids the risk of liver damage that may be caused by the combined use of multiple Chinese medicinal ingredients, and improves the safety of the drug and patient compliance.

[0018] (3) The preparation method of the present invention has simple process, low cost, is suitable for large-scale production, and can meet a wide range of market demands. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0020] Figure 1 The figure shows the inhibitory effect of the edible-medicinal composition on HepG2 tumor cells, wherein A is a visual graph of the inhibition of HepG2 tumor cells, and B is the inhibition rate of HepG2 tumor cells.

[0021] Figure 2The figure shows the inhibitory effect of the medicinal and edible composition on A549 tumor cells, wherein A is a visual graph of the inhibition of A549 tumor cells, and B is the inhibition rate of A549 tumor cells.

[0022] Figure 3 The size of HepG2 tumor after drug administration. Among them, A is the visual diagram of HepG2 tumor size, B is the volume of HepG2 tumor, and C is the weight of HepG2 tumor.

[0023] Figure 4 The following table shows the size of A549 tumor after administration. A is a visual diagram of A549 tumor size, B is the volume of A549 tumor, and C is the weight of A549 tumor.

[0024] Figure 5 Pathological analysis of HepG2 inoculated tumors.

[0025] Figure 6 Pathological analysis of A549 inoculated tumors. DETAILED DESCRIPTION

[0026] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0027] It should be understood that the terms described herein are intended only to describe particular embodiments and are not intended to limit the present invention. In addition, for numerical ranges herein, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Each smaller range between any intermediate value within a stated value or stated range and any other stated value or intermediate value within the stated range is also encompassed by the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded within the scope.

[0028] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of any conflict with any incorporated document, the contents of this specification shall prevail.

[0029] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from the present invention. The present description and examples are intended to be illustrative only.

[0030] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0031] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or are publicly available.

[0032] An embodiment of the present invention provides a medicinal and edible composition with anti-tumor effect, comprising the following ingredients in parts by weight: 10-30 parts of dandelion, 5-15 parts of ganoderma lucidum, 20-40 parts of cordyceps militaris, 10-30 parts of chrysanthemum, 20-40 parts of honeysuckle, 10-30 parts of tangerine peel, 20-40 parts of dendrobium officinale and 20-40 parts of nutmeg.

[0033] In some specific embodiments, the following ingredients are included in parts by weight: 1-100 parts of dandelion, 1-90 parts of ganoderma lucidum, 1-80 parts of cordyceps militaris, 1-90 parts of chrysanthemum, 1-90 parts of honeysuckle, 1-90 parts of tangerine peel, 1-90 parts of dendrobium officinale and 1-90 parts of nutmeg.

[0034] In some specific embodiments, the following ingredients are included in parts by weight: 20-80 parts of dandelion, 30-80 parts of ganoderma lucidum, 20-80 parts of cordyceps militaris, 30-80 parts of chrysanthemum, 30-80 parts of honeysuckle, 30-80 parts of tangerine peel, 30-80 parts of dendrobium officinale and 30-80 parts of nutmeg.

[0035] In some specific embodiments, the following ingredients are further included in parts by weight: 20-40 parts of shiitake mushrooms, 5-15 parts of chestnut mushrooms, 10-20 parts of American ginseng, 1-10 parts of licorice, 1-10 parts of kudzu root, 10-30 parts of turmeric, 15-25 parts of cornus officinalis, 5-15 parts of cranberries, 5-15 parts of mulberries and 5-15 parts of lemons.

[0036] In some specific embodiments, the following ingredients are further included in parts by weight: 1-40 parts of shiitake mushrooms, 1-25 parts of chestnut mushrooms, 1-20 parts of American ginseng, 1-40 parts of licorice, 1-40 parts of kudzu root, 1-20 parts of turmeric, 1-25 parts of cornus officinalis, 1-25 parts of cranberries, 1-30 parts of mulberries and 1-25 parts of lemons.

[0037] In some specific embodiments, 10-30 parts of shiitake mushrooms, 5-20 parts of chestnut mushrooms, 10-20 parts of American ginseng; 30-40 parts of licorice, 30-40 parts of kudzu root, 10-20 parts of turmeric, 10-20 parts of cornus officinalis, 15-25 parts of cranberries, 20-30 parts of mulberries and 10-25 parts of lemons.

[0038] In some specific embodiments, the ingredients are included in the following parts by weight: 20 parts of dandelion, 10 parts of Ganoderma lucidum, 30 parts of Cordyceps militaris, 20 parts of chrysanthemum, 30 parts of honeysuckle, 20 parts of orange peel, 30 parts of Dendrobium officinale, 30 parts of nutmeg, 30 parts of shiitake mushroom, 10 parts of chestnut mushroom, 15 parts of American ginseng, 5 parts of licorice, 5 parts of Pueraria root, 20 parts of turmeric, 20 parts of Cornus officinalis, 10 parts of cranberry, 10 parts of mulberry and 10 parts of lemon.

[0039] In some specific embodiments, the medicine-food composition further includes: water, a filler, a binder, a diluent, a lubricant, a glidant, a coating agent, or a mixture of two or more thereof.

[0040] In some specific embodiments, the edible and medicinal composition further includes: starch, isomaltooligosaccharide, maltodextrin, xylitol, microcrystalline cellulose, erythritol, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, benzoic acid or ethanol, or a mixture of two or more thereof.

[0041] The present invention also provides a method for preparing the edible and medicinal composition, comprising the following steps:

[0042] (1) mixing and crushing dandelion, Ganoderma lucidum, Cordyceps militaris, chrysanthemum, honeysuckle, orange peel, Dendrobium officinale and nutmeg, and extracting with ethanol to obtain extract I;

[0043] (2) Mixing and grinding shiitake mushrooms, chestnut mushrooms, American ginseng, liquorice, kudzu root, turmeric, and cornus officinalis to obtain a powder; blending cranberries, mulberries, and lemons to obtain a coarse pulp; mixing the powder and the coarse pulp, and extracting with ethanol to obtain extract II;

[0044] (3) Combine the extracts I and II, evaporate and concentrate, and add auxiliary materials to prepare granules.

[0045] In some specific embodiments, the auxiliary materials include 10 parts of erythritol and 10 parts of maltodextrin.

[0046] The embodiment of the present invention also provides the use of the medicine-food combination in the preparation of anti-tumor drugs.

[0047] In some specific embodiments, the dosage form of the drug comprises granules.

[0048] In some specific embodiments, the tumors include lung cancer and liver cancer.

[0049] The present invention discloses an anti-tumor medicinal and edible composition and its application. The composition is composed of a mixture of a main ingredient and auxiliary ingredients. The main ingredients are dandelion, ganoderma lucidum, cordyceps militaris, chrysanthemum, honeysuckle, tangerine peel, dendrobium officinale, and nutmeg; supplemented with shiitake mushrooms, chestnut mushrooms, American ginseng, licorice, kudzu root, turmeric, cornus officinalis, and fruits rich in proanthocyanidins such as cranberries, mulberries, and lemons to adjust the taste and assist in anti-tumor effects. The specific steps are as follows: all the above raw materials are extracted and concentrated with purified water, mixed, and then an appropriate amount of maltodextrin and erythritol are added to the mixture, mixed evenly, and wet granulated to obtain granules of the anti-tumor composition. The medicinal and edible composition produced by the present invention is highly safe, has a scientific formula, and a stable process. It can have significant anti-tumor effects and has significant social and economic benefits. The addition of fruits rich in proanthocyanidins adjusts the taste and assists in anti-tumor effects.

[0050] The present invention's anti-tumor medicinal and edible botanical composition utilizes extracts of dandelion, Ganoderma lucidum, Cordyceps militaris, chrysanthemum, honeysuckle, tangerine peel, Dendrobium officinale, and nutmeg as its primary ingredients; supplemented with extracts of shiitake mushroom, chestnut mushroom, American ginseng, licorice, kudzu root, turmeric, and cornus officinalis, as well as extracts of proanthocyanidins-rich fruits such as cranberry, mulberry, and lemon. This scientific combination of medicinal and edible botanicals is a pioneering discovery of the potential anti-tumor properties of tangerine peel, Dendrobium officinale, nutmeg, and cornus officinalis. Through synergistic effects with other medicinal and edible ingredients, the composition achieves significant anti-tumor effects, enhances immunity, and improves the patient's physical fitness, providing safe and effective support for adjuvant tumor treatment and enhancing patients' quality of life.

[0051] In order to improve the convenience of daily use for patients, the anti-tumor medicine-food composition of the present invention can be added with auxiliary materials and the dosage form can be adjusted as needed.

[0052] The anti-tumor medicine-food composition of the present invention has significant application effect in anti-tumor treatment. It can not only enhance the immune function, but also improve the patient's physical condition, and has high safety and good patient compliance.

[0053] The sources of raw materials in each embodiment of the present invention are as follows:

[0054] The manufacturer of raw materials such as dandelion, Ganoderma lucidum, Cordyceps militaris, chrysanthemum, honeysuckle, orange peel, iron stone, nutmeg, etc. is Bozhou Yiyuan Biotechnology Co., Ltd.; raw materials such as shiitake mushroom, chestnut mushroom, American ginseng, licorice, kudzu root, turmeric, cornus officinalis, cranberry, mulberry, lemon, etc. are purchased from Shaanxi Tiandiyuan Biotechnology Co., Ltd.

[0055] Erythritol, maltodextrin (food grade): The manufacturer is Jiangsu Jinheyuan Bioengineering Co., Ltd.

[0056] Ethanol (food grade): The manufacturer is Zhenjiang Jinsheng Scientific Instruments Co., Ltd.

[0057] Example 1

[0058] A medicinal and edible composition with anti-tumor effect, comprising the following ingredients in parts by weight: 20 parts of dandelion, 10 parts of ganoderma lucidum, 30 parts of cordyceps militaris, 20 parts of chrysanthemum, 30 parts of honeysuckle, 20 parts of tangerine peel, 30 parts of dendrobium officinale, 30 parts of nutmeg, 30 parts of shiitake mushroom, 10 parts of chestnut mushroom, 15 parts of American ginseng, 5 parts of liquorice, 5 parts of kudzu root, 20 parts of turmeric, 20 parts of cornus officinalis, 10 parts of cranberry, 10 parts of mulberry and 10 parts of lemon.

[0059] After extraction and concentration, 20 parts of auxiliary materials are added and spray-dried to prepare granules for auxiliary anti-tumor granules. The auxiliary materials include 10 parts of maltodextrin and 10 parts of erythritol.

[0060] The method for preparing granules comprises the following steps:

[0061] (1) Dry dandelion, ganoderma lucidum, cordyceps militaris, chrysanthemum, honeysuckle, orange peel, dendrobium officinale and nutmeg in the shade or in the sun, and grind into powder in a grinder;

[0062] (2) The obtained raw material powder was added with 50% ethanol at a material-liquid mass ratio of 1:40 and mixed evenly; ultrasonic extraction was performed in a 70°C water bath for 30 minutes, and the extraction was repeated 4 times. After extraction, centrifugation was performed to obtain a supernatant and a precipitate. The supernatant was the extract I.

[0063] (3) Dry shiitake mushrooms, chestnut mushrooms, American ginseng, licorice, kudzu root, turmeric, and cornus officinalis in the shade or in the sun; wash, peel, and remove the core of cranberries, mulberries, and lemons;

[0064] (4) Shade-dried or sun-dried shiitake mushrooms, chestnut mushrooms, American ginseng, licorice, kudzu root, turmeric, and cornus officinalis are put into a grinder and ground into powder; cranberry, mulberry, and lemon pulp are added with water in a mass ratio of 1:10 to obtain a coarse pulp;

[0065] (5) Mixing the raw material powder and the coarse pulp obtained in steps (3) and (4), adding 50% ethanol at a material-liquid mass ratio of 1:40, and mixing thoroughly; placing in a 70°C water bath and ultrasonically extracting for 40 minutes, repeating the extraction three times, and centrifuging after extraction to obtain a supernatant and a precipitate, wherein the supernatant is extract II;

[0066] (6) Combine the extracts I and II, place them on a rotary evaporator, evaporate and concentrate to 1 / 10 of the original volume, add auxiliary materials, mix well, and then spray dry to obtain the corresponding solid powder.

[0067] The method for preparing the granules is a conventional method and will not be described in detail here.

[0068] 2. Inhibitory effect of the medicinal and edible composition on cancer cells and tumor growth in mice

[0069] The MTT method was used to detect the anti-tumor activity of the medicinal and edible composition prepared in Example 1 on various cells. HepG2 and A549 cells in the exponential growth phase were placed in DMEM high-glucose medium and trypsin digestion solution and resuspended by gently pipetting. 4×10 5 Cell suspensions of 10 cells / mL were uniformly seeded into 96-well culture plates at a density of 100 μL / well and cultured in an incubator (37° C., 5% CO 2 ) for 24 h.

[0070] The edible and medicinal composition prepared in Example 1 was gradiently diluted with DMEM high-glucose medium without FBS to five different concentrations of 1 μg / ml, 5 μg / ml, 25 μg / ml, 50 μg / ml, and 100 μg / ml. After culturing in a cell culture incubator (37° C., 5% CO 2 ) for 24 h, the edible and medicinal composition prepared in Example 1 at different concentrations was added to the cell culture wells and cultured for 48 h. The culture medium was replaced every 24 h, with 100 μL of culture medium per well each time.

[0071] The cells in the normal DMEM high glucose medium (without any drugs) without FBS were used as the negative control group. Three replicate wells were set up for each sample at different concentrations.

[0072] The culture plates were incubated in an incubator (37°C, 5% CO2) for 72 hours. After 72 hours of incubation, 20 μL of MTT solution (5 mg / mL) was precisely pipetted into each well and incubated for another 4 hours. The supernatant was then carefully aspirated, and 100 μL of DMSO was added to completely dissolve any purple crystals (formazan). The absorbance of each well was measured within 10 minutes using a Biotek Epoch microplate reader.

[0073] Cell viability was evaluated using the cell growth inhibition rate as an indicator. By calculating the IC50 value, the experimental results showed that with the increase of sample concentration, the growth inhibition rate of HepG2 and A549 also increased.

[0074] 3. Subcutaneous inoculation of tumor cells

[0075] First, disinfect the skin at the inoculation site of BALB / c nude mice (SPF grade). Use a 1mL syringe to precisely draw 0.2mL of each A549 and HepG2 cell suspension from a centrifuge tube. Grasp the nude mouse's neck with your left hand and gently lift the skin near the tail. Inoculate the tumor cells subcutaneously on the back near the tail. Inject slowly. A noticeable bump will appear after injection. Use a sterile cotton swab to press the needle point for 10 seconds to prevent the cell suspension from leaking out.

[0076] A total of 50 nude mice were inoculated in this experiment. Four days after subcutaneous inoculation of A549 and HepG2 cells, small, oval or round nodules approximately 6 mm in diameter appeared at the inoculation site in all nude mice. These nodules did not decrease in size, indicating successful tumor inoculation.

[0077] The nude mice bearing A549 cells and HepG2 cells that were successfully inoculated were randomly divided into 5 groups, with 5 mice in each group, namely the high-dose group, medium-dose group, low-dose group, paclitaxel-positive drug group and model group of the medicine-food combination. In addition, nude mice (5 mice) and nude mice (5 mice) that were not inoculated with A549 and HepG2 were used as blank control groups.

[0078] The positive drug and high-dose, medium-dose and low-dose Example 1 were dissolved in a solvent and intraperitoneally administered once every four days at a dose of 20 mg / kg.

[0079] The blank control group and the model group were not given any medication.

[0080] Dosing began on the fifth day after inoculation and continued for 22 days. Nude mice in each group were sacrificed and dissected on the second day after drug withdrawal for tumor location or tumor measurement. Tumor tissue from tumor-bearing nude mice was then immersed in 4% formalin, washed with pH 7.4 PBS, and routinely paraffin-embedded before being cut into thin sections (5 μm). The sections were then stained with hematoxylin-eosin (HE). The pathological structure of the tumor tissue was observed using an electron microscope.

[0081] like Figure 3-4 As shown, the positive drug and different concentrations of Chinese herbal medicine samples had different degrees of inhibitory effects on the growth of subcutaneous tumors in nude mice. Compared with the model group, different concentrations of Chinese herbal medicine samples showed significant differences in the tumor weight of nude mice (P<0.01), and all of them could significantly inhibit the growth of subcutaneous tumors in nude mice. The figure below shows the size of solid tumors in nude mice after drug administration. The figure can be more intuitively found that after 22 days of drug administration, the tumor volume of nude mice in the model group increased significantly, and the tumor volume decreased significantly after intracavitary injection of positive drugs and high, medium and low concentrations of Chinese herbal medicine. Therefore, the developed solid beverage has a good therapeutic effect on tumors in tumor-bearing mice.

[0082] Depend on Figure 5-6 In the model group, cancer cells were diffusely distributed, irregularly structured, and relatively densely packed, with inflammatory cell infiltration visible around them. Compared to the model group, after administration of the solid beverage, cancer cells were more loosely distributed, with a significant number of tumor cells undergoing necrosis, forming larger and more numerous vacuoles, and with a larger area of necrosis accompanied by a significant infiltration of inflammatory cells. These results suggest that the solid beverage can promote tumor cell necrosis, have an inhibitory effect on cancer cells, and promote cancer cell necrosis.

[0083] Obviously, the above embodiments of the present invention are merely examples for the purpose of clearly illustrating the present invention and are not intended to limit the implementation methods of the present invention. A person skilled in the art will be able to make other variations or modifications based on the above description. It is not necessary and impossible to enumerate all implementation methods here. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the claims of the present invention.

Claims

1. A medicinal and edible composition with anti-tumor effect, characterized in that: The invention comprises the following ingredients in parts by weight: 10-30 parts of dandelion, 5-15 parts of ganoderma lucidum, 20-40 parts of cordyceps militaris, 10-30 parts of chrysanthemum, 20-40 parts of honeysuckle, 10-30 parts of tangerine peel, 20-40 parts of dendrobium officinale and 20-40 parts of nutmeg.

2. The medicine-food composition according to claim 1, characterized in that The invention also includes the following ingredients in parts by weight: 20-40 parts of shiitake mushrooms, 5-15 parts of chestnut mushrooms, 10-20 parts of American ginseng, 1-10 parts of licorice, 1-10 parts of kudzu root, 10-30 parts of turmeric, 15-25 parts of cornus officinalis, 5-15 parts of cranberries, 5-15 parts of mulberries and 5-15 parts of lemons.

3. The medicine-food composition according to claim 1, characterized in that The invention comprises the following ingredients in parts by weight: 20 parts of dandelion, 10 parts of ganoderma lucidum, 30 parts of cordyceps militaris, 20 parts of chrysanthemum, 30 parts of honeysuckle, 20 parts of tangerine peel, 30 parts of dendrobium officinale, 30 parts of nutmeg, 30 parts of shiitake mushroom, 10 parts of chestnut mushroom, 15 parts of American ginseng, 5 parts of liquorice, 5 parts of kudzu root, 20 parts of turmeric, 20 parts of cornus officinalis, 10 parts of cranberry, 10 parts of mulberry and 10 parts of lemon.

4. The method for preparing the edible and medicinal composition according to any one of claims 1 to 3, wherein: The following steps are involved: (1) mixing and crushing dandelion, Ganoderma lucidum, Cordyceps militaris, chrysanthemum, honeysuckle, orange peel, Dendrobium officinale and nutmeg, and extracting with ethanol to obtain extract I; (2) Mixing and grinding shiitake mushrooms, chestnut mushrooms, American ginseng, liquorice, kudzu root, turmeric, and cornus officinalis to obtain a powder; blending cranberries, mulberries, and lemons to obtain a coarse pulp; mixing the powder and the coarse pulp, and extracting with ethanol to obtain extract II; (3) Combine the extracts I and II, evaporate and concentrate, and add auxiliary materials to prepare granules.

5. The preparation method according to claim 4, characterized in that The auxiliary materials include 10 parts of erythritol and 10 parts of maltodextrin.

6. Use of the medicine-food composition according to any one of claims 1 to 3 in the preparation of anti-tumor drugs.

7. The use according to claim 6, characterized in that The dosage form of the drug includes granules.

8. The use according to claim 6, characterized in that The tumors include lung cancer and liver cancer.

Images